Quickly find freely available drug and population models in our PBPK model repository.
The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.>
You can use a suffix operator (*) as the placeholder for end of a term. The query must start with at least one alphanumeric character before the suffix operator. E.g., Rifam* will get you “Rifampicin” and “Rifampin”. For more advanced searching tips click here.
Brand Name(s) include: Viread
Disease: HIV
Drug Class: Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Date of Review: 2020
Number of Models Reviewed: 3
Number of Models added to the Repository: 3
Publication |
De Sousa Mendes, M., Chetty, M. Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment. Drugs R D 19, 339–350 (2019). |
Simcyp Version |
V17 |
Absorption Model |
|
Volume of Distribution Details |
|
Route of Elimination |
|
Perpetrator DDI |
|
Advantages and Limitations |
|
Model Compound Files |
|
Publication |
Liu S N, Desta Z, Gufford B T. Probenecid‐Boosted Tenofovir: A Physiologically‐Based Pharmacokinetic Model‐Informed Strategy for On‐Demand HIV Preexposure Prophylaxis[J]. CPT: pharmacometrics& systems pharmacology, 2020, 9(1): 40- 47. |
Simcyp Version |
V15 |
Absorption Model |
|
Volume of Distribution Details |
|
Route of Elimination |
|
Perpetrator DDI |
|
Advantages and Limitations |
|
Model Compound Files |
|
Publication |
De Sousa Mendes M, Hirt D, Urien S, Valade E, Bouazza N, Foissac F, Blanche S, Treluyer JM, Benaboud S. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. Br J Clin Pharmacol. 2015 Nov;80(5):1031-41. |
Simcyp Version |
V13 |
Published Model Application |
Prediction of exposure in pregnancy |
Absorption Model |
|
Volume of Distribution Details |
|
Route of Elimination |
|
Perpetrator DDI |
|
Advantages and Limitations |
|
Model Compound Files |
|
Brand Name(s) include: Basoquin, Camoquin, Flavoquin, Coarsucam
Disease: Malaria
Drug Class: Antimalarials
Date Updated: June 2021
Absorption Model |
First-Order |
Volume of Distribution |
Full PBPK (Method 2) |
Route of Elimination |
CYP2C8 = 72%; Additional HLM = 28% |
Perpetrator DDI |
|
Validation |
|
Limitations |
|
Updates in V19 |
|
13 |